LS
CRL icon

Leelyn Smith’s Charles River Laboratories CRL Stock Holding History

Leelyn Smith’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-552
Closed -$118K – 476
2022
Q2 		$118K Buy
552
+276
+100% +$67.4K 0.03% 146
2022
Q1 		$78K Hold
276
– – 0.02% 175
2021
Q4 		$104K Hold
276
– – 0.03% 163
2021
Q3 		$114K Hold
276
– – 0.03% 148
2021
Q2 		$102K Hold
276
– – 0.03% 161
2021
Q1 		$80K Sell
276
-25
-8% -$6.95K 0.02% 190
2020
Q4 		$75K Buy
301
+45
+18% +$10.7K 0.02% 184
2020
Q3 		$58K Sell
256
-35
-12% -$7.26K 0.02% 181
2020
Q2 		$51K Sell
291
-33
-10% -$5.27K 0.02% 199
2020
Q1 		$41K Buy
+324
New +$48.6K 0.02% 172

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Leelyn Smith's CRL Position: Q3 2022 in Review

Leelyn Smith sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 552 shares — an estimated $118K sold.

Leelyn Smith first reported a position in CRL in Q1 2020 and held it in 10 quarters. The position peaked at $118K in Q2 2022. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Leelyn Smith reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
  • Leelyn Smith sold 552 Charles River Laboratories shares in Q3 2022, an estimated $118K.
  • Leelyn Smith first reported a position in Charles River Laboratories in Q1 2020 and held it in 10 quarters.
  • Leelyn Smith's Charles River Laboratories position peaked at $118K in Q2 2022.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Leelyn Smith's 13F filing for Q3 2022, filed 14 Nov 2022.